$MCIG Introduces Kavva Vape & High Grade CBD Vape Juice Line

mCig, Inc. is pleased to unveil its own branded CBD Vape pen and e-liquid that were developed in house. The new product, Kavva Vape, is an e-liquid that combines the healing powers of CBD hemp oil and Kava extract. Kava Kava (Piper methysticum) belongs to the same family as pepper and is a tall shrub native to the tropical islands of the South Pacific Ocean. Kava is used effectively to reduce anxiety, depression, and insomnia and promotes clear thinking, calmness, relaxed muscles, and a sense of well-being. Kavva Vape is available to order now in prefilled 1 ml tanks and comes in two fabulous flavors: Mint and Cool Citrus. Kavva Vape will be priced at $24.95 for a 1ml tank or $34.95 in combination with the new mCig CBD Vape pen.

“We spent about 9 months not only developing our own CBD products, but learning the market, listening to customer feedback and reviews, and building a national retail presence. We currently have more than 3000 clients who have tried our different CBD products and more than 300 open wholesale accounts that are pushing our different product lines to consumers. We continue to distribute the Just Chill brand of products as this is our current number one seller, but we want to have more direct control of the products that we are introducing to our customers. Controlling pricing across the board will allow us to have higher margins and make our business more profitable”, said Paul Rosenberg, CEO of mCig, Inc.

mCig is also proud to announce that the company began to distribute another new product, Naturally Flavored High Grade CBD E-Juice, developed by Vitacig Inc. (VTCQ). The two vape oils or e-juices contain a perfected blend of CBD-rich hemp oil and natural flavorings. These are now available in the following flavors and size:

1. Cool Citrus Vape 10ml bottle containing 50mg CBD
2. Strawberry Vape 10ml bottle containing 50mg CBD

These new products and other mCig branded accessories are sold online at: www.mcig.org,www.vitacbd.com, www.vitacig.org, www.chillcbdoil.com or through affiliate websites and select brick and mortar locations.

“As you know, mCig owns 47% of VitaCig Inc. and we are working together on many initiatives including product development, marketing, and sales. We are currently looking for strategic partnerships to diversify our offerings including reducing our stake in Vitacig Inc. for the benefit of VitaCig and mCig shareholders. We will soon release updates about substantial progress in our grow division, new product releases, and other projects that will make 2016 an exciting year for the company. I am working with a few groups right now to push these plans forward and in combination with our non-dilutive structure we feel very confident about what the future holds,” stated Paul Rosenberg, CEO.

About mCig, Inc.

Headquartered in Beverly Hills, CA, mCig, Inc. (OTCQB: MCIG) is a leading provider of advanced technologies and solutions to the global cannabis industry. mCig manufactures and markets best-selling portable and home vaporizers, extraction related equipment, CBD Rich Hemp Oil-derived products, and related nutraceuticals based on natural compounds found in Cannabis and Hemp plants. The company owns the mCig and Vapolution brands, and has a 47% stake in VitaCig (VTCQ), makers of the VitaStik, a disposable vitamin vaporizer. The company believes that a well-regulated marijuana industry is emerging as more states follow the lead of Alaska, Colorado, Oregon, and Washington in legalizing marijuana. A similar trend is developing within the CBD and Hemp industries following overwhelming consumer demand.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.